Katragadda HR, Fullana A, Sidhu S, Carbonell-Barrachina A (2010) Emissions of volatile aldehydes from heated cooking oils
For weight loss, GLP-1s are the first clinical choice: Tirzepatide and Semaglutide are the tools that actually drive fat reduction and appetite regulation
It does this by reducing global protein synthesis and enhancing gene expression targeted toward cellular recovery (chaperones, protein folding, etc.) [225, 226]
This post-surgical gut paralysis renders some patients unable to eat while saddling them with serious constipation, bloating, and discomfort and keeping them in hospital much longer than they otherwise would have been
The favorable results from the placebo-controlled FLOW trial, conducted with semaglutide 1.0 mg in patients with T2D and chronic kidney disesase (CKD), are about to be disclosed, while ongoing dedicated trials will further explore the effects of OW semaglutide 2.4 mg (NCT04889183) and tirzepatide (NCT05536804) on kidney function parameters in obese/overweight individuals at high risk of CKD progression regardless of T2D
